Dusp6-flox Mouse
一般名
Dusp6-flox
製品ID
S-CKO-13779
背景情報
C57BL/6JCya
系統ID
CKOCMP-67603-Dusp6-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Dusp6-flox Mouse(カタログ番号S-CKO-13779)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Dusp6-flox
系統ID
CKOCMP-67603-Dusp6-B6J-VA
遺伝子名
製品ID
S-CKO-13779
遺伝子別名
MKP3, MKP-3, PYST1, 1300019I03Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 10
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000020118
NCBIトランスクリプトID
NM_026268
ターゲット領域
Exon 1~2
有効領域の大きさ
~2.0 kb
遺伝子研究の概要
Dusp6, also known as MKP3, is a dual-specificity phosphatase with a conserved function in the dephosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) [2]. It is involved in multiple signaling pathways, including the MAPK pathway, and plays a crucial role in various biological processes, such as cell proliferation, differentiation, and inflammation [1,2,4]. Genetic models, like knockout mouse models, have been instrumental in studying its functions.
In myeloproliferative neoplasms (MPNs) transforming to secondary acute myeloid leukemia (sAML), Dusp6 expression is aberrantly increased. Pharmacologic targeting of Dusp6 inhibits S6 and JAK-STAT signaling, reduces inflammatory cytokine production, and suppresses disease development in MPN mouse models and sAML patient-derived xenografts (PDXs) [1].
In the context of myocardial infarction, Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase. Mechanistically, Dusp6 is transcriptionally activated by p38-C/EBPβ signaling and maintains p-p38 activity [2].
In HER2+ breast cancer, Dusp6 expression is induced during re-proliferation from dormant drug-tolerant cells. Its pharmacological blockade prevents therapy tolerance development under HER2 inhibitor therapy [3].
In MAPK pathway-driven cancers, dual inactivation of Dusp4 and Dusp6 impairs the growth of NRAS and BRAF mutant cells [4].
In colorectal cancer, Dusp6 can dephosphorylate Notch1, regulating its stability and transcriptional activity, and promoting cancer cell proliferation [5].
In colon cancer, PKN2 can inhibit M2 phenotype polarization of tumor-associated macrophages via regulating the Dusp6-Erk1/2 pathway [6].
Mutations in Dusp6 are identified in individuals with congenital hypogonadotropic hypogonadism [7].
Dusp6 deficiency attenuates neurodegeneration after global cerebral ischemia, as Dusp6 is induced in hippocampal CA1 neurons after ischemia, and its deficiency enhances Erk1/2 phosphorylation and nuclear translocation [8].
In Xenopus, Dusp6 is required for pre-placodal ectoderm formation by mediating FGF signaling [9].
In renal cell carcinoma, diminished Dusp6 expression is linked to disease progression, and calcium saccharate can enhance Dusp6 expression, inhibiting tumor cell proliferation and metabolic rewiring [10].
In conclusion, Dusp6 is a key regulator in multiple biological processes, mainly through its function in dephosphorylating ERK1/2. The use of Dusp6 knockout or conditional knockout mouse models has revealed its significance in diseases such as hematological malignancies, cardiovascular diseases, breast cancer, various cancers, neurodegenerative diseases, and developmental processes. Understanding Dusp6 provides potential therapeutic targets for these diseases.
References:
1. Kong, Tim, Laranjeira, Angelo B A, Yang, Kangning, Huang, Sidong, Oh, Stephen T. 2022. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. In Nature cancer, 4, 108-127. doi:10.1038/s43018-022-00486-8. https://pubmed.ncbi.nlm.nih.gov/36581736/
2. Zhou, Xiaohai, Zhang, Chenyang, Wu, Xueying, Zhu, Xiaojun, Xiong, Jing-Wei. 2022. Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction. In Nature communications, 13, 6672. doi:10.1038/s41467-022-33631-z. https://pubmed.ncbi.nlm.nih.gov/36335128/
3. Momeny, Majid, Tienhaara, Mari, Sharma, Mukund, Kurppa, Kari J, Westermarck, Jukka. 2024. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. In EMBO molecular medicine, 16, 1603-1629. doi:10.1038/s44321-024-00088-0. https://pubmed.ncbi.nlm.nih.gov/38886591/
4. Ito, Takahiro, Young, Michael J, Li, Ruitong, Zamanighomi, Mahdi, Sellers, William R. 2021. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. In Nature genetics, 53, 1664-1672. doi:10.1038/s41588-021-00967-z. https://pubmed.ncbi.nlm.nih.gov/34857952/
5. Png, Chin Wen, Weerasooriya, Madhushanee, Li, Heng, Tan, Ker-Kan, Zhang, Yongliang. 2024. DUSP6 regulates Notch1 signalling in colorectal cancer. In Nature communications, 15, 10087. doi:10.1038/s41467-024-54383-y. https://pubmed.ncbi.nlm.nih.gov/39572549/
6. Cheng, Yang, Zhu, Yun, Xu, Jiajia, Geng, Lanlan, Gong, Sitang. 2018. PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway. In Molecular cancer, 17, 13. doi:10.1186/s12943-017-0747-z. https://pubmed.ncbi.nlm.nih.gov/29368606/
7. Miraoui, Hichem, Dwyer, Andrew A, Sykiotis, Gerasimos P, Lage, Kasper, Pitteloud, Nelly. . Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. In American journal of human genetics, 92, 725-43. doi:10.1016/j.ajhg.2013.04.008. https://pubmed.ncbi.nlm.nih.gov/23643382/
8. Weng, Yi-Chinn, Huang, Yu-Ting, Chiang, I-Chen, Tan, Tse-Hua, Chou, Wen-Hai. 2023. DUSP6 Deficiency Attenuates Neurodegeneration after Global Cerebral Ischemia. In International journal of molecular sciences, 24, . doi:10.3390/ijms24097690. https://pubmed.ncbi.nlm.nih.gov/37175394/
9. Tsukano, Kohei, Yamamoto, Takayoshi, Watanabe, Tomoko, Michiue, Tatsuo. 2022. Xenopus Dusp6 modulates FGF signaling to precisely pattern pre-placodal ectoderm. In Developmental biology, 488, 81-90. doi:10.1016/j.ydbio.2022.05.009. https://pubmed.ncbi.nlm.nih.gov/35598626/
10. Liu, Huan, Wang, Longsheng, Shi, Xiaokai, Chen, Yonghui, Zhang, Tao. 2024. Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway. In Biochemical pharmacology, 224, 116247. doi:10.1016/j.bcp.2024.116247. https://pubmed.ncbi.nlm.nih.gov/38697311/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
